ClinicalTrials.gg
CompletedNCT06318117Updated Jan 30, 2026

Reason for Prescribing Rice Infant Formula

An observational study in Infant Formula, sponsored by Mead Johnson Nutrition. Completed at 17 sites in France. Open to participants aged 6 Months to 36 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Mead Johnson Nutrition (part of Reckitt) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
41
Ages
6 Months to 36 Months
Sex
All
01

Study summary

The main purpose of this study is to describe the pattern of RIF consumption in real life conditions, whatever the reasons of initiation and the chosen formula. The main objective is to study the reasons for prescribing a RIF during the first year of life, as per the pediatrician. Consumption started before 6 months of age, when milk and infantile formulas predominates in the baby's feeding, is of particular interest.

Read the detailed description

The main purpose of this study is to describe the pattern of RIF consumption in real life conditions, whatever the reasons of initiation and the chosen formula. The main objective is to study the reasons for prescribing a RIF during the first year of life, as per the pediatrician. Consumption started before 6 months of age, when milk and infantile formulas predominates in the baby's feeding, is of particular interest. Secondary objectives are to describe the modalities of feeding before, during and after consuming the RIF, to describe the growth of children who have consumed a RIF for at least 1 month, on the basis of anthropometric data collected during the first year of life. As a second intention, this study also aims to monitor the evolution of child's digestive and allergic symptoms, if any, and the sociodemographic characteristics of the infant's family.

02

Conditions studied

  • Infant Formula

Keywords

  • Rice Formula
03

In context

Lead sponsor

Mead Johnson Nutrition is the lead sponsor of 58 studies on the registry; 1 is open to participants now.

First submitted after Mead Johnson Nutrition became part of Reckitt.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

120 infants will be recruited for this study, according to the following inclusion and non-inclusion criteria, including at least 60 infants who started the RIF before the age of 6 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child aged between 6 and 36 months,
  • Child who has already consumed a RIF for at least one month, or still consuming a RIF, or who will benefit from taking a RIF, according to the pediatrician,
  • Legal representatives (parents/guardians) deemed capable of following the requirements of the protocol and have given their consent orally.

Exclusion criteria

Exclusion Criteria:

  • Child with a and significant abnormality in the medical history or on physical examination;
  • Child who has been hospitalized in a neonatology unit (due to prematurity, malformation or neonatal pathology), or born with a low birth weight (≤ 2,500 g);
  • For children not diversified at the time of starting RIF: mixed feeding with RIF and breast milk and/or infant formula based on cow's milk;
  • Child born to minor parent(s);
  • Infant or infant's family unable to comply with study protocol or procedures, in the judgment of the investigator;
  • Participation in any other clinical trial prior to inclusion;
  • Refusal of the Parents / legal representatives of the child, or who do not master the French language well enough to understand the information letter.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
41 participants (actual)
Patient registry
No

Groups and cohorts

  • Rice infant formula started before age of 6 months

    After inclusion (V1), infants will return for a V2 visit at 12 months (± 30 days) of age (according to the child's regular appointment calendar). No visit is imposed by the protocol. Anthropometric data from visits to the pediatrician carried out between V1 and V2 will be collected from medical records, as well as the date of cessation of RIF, if applicable. Retrospective data will be collected from medical files (anthropometric data, medical and feeding history) and from parents' and investigator's recall.

    Other: Rice infant formula

  • Rice infant formula started after age of 6 months

    After inclusion (V1), infants will return for a V2 visit at 12 months (± 30 days) of age (according to the child's regular appointment calendar). No visit is imposed by the protocol. Anthropometric data from visits to the pediatrician carried out between V1 and V2 will be collected from medical records, as well as the date of cessation of RIF, if applicable. Retrospective data will be collected from medical files (anthropometric data, medical and feeding history) and from parents' and investigator's recall.

    Other: Rice infant formula

Interventions

  • OtherRice infant formula

    Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.

06

What researchers measure

Primary outcomes

  1. Questionnaire - reason for prescribing a RIF during the 1st year of life.

    The main objective is to describe the main reason for prescribing a RIF by the pediatrician during the 1st year of life.

    Time frame: 1 to 7 months

Secondary outcomes

  1. Questionnaire - Reason for prescribing a RIF in first 6 months of life

    o describe the main reason for prescribing a RIF by the pediatrician during the 1st 6 months of life.

    Time frame: up to 365 days of age

  2. Questionnaire - Diet characteristics

    To describe the conditions of RIF consumption during the follow-up, and the other main characteristics of the diet.

    Time frame: up to 365 days of age

  3. Growth z-scores body mass index (BMI)-for-age

    body mass index (BMI)-for-age

    Time frame: up to 365 days of age

  4. Growth z-score

    Weight-for-age z-score

    Time frame: up to 365 days of age

  5. Growth z-score

    Length/Height-for-age z-score

    Time frame: up to 365 days of age

  6. Growth z-score

    Weight-for-length/height z-score

    Time frame: up to 365 days of age

  7. Growth z-score

    Head circumference-for-age z-score

    Time frame: up to 365 days of age

  8. Questionnaire - Evolution of digestive and allergic symptoms

    To describe the evolution of digestive and allergic symptoms during follow-up.

    Time frame: up to 365 days of age

  9. Socio-demographic characteristics

    To describe the socio-demographic characteristics of the infants' families

    Time frame: up to 365 days of age

07

Study locations

17 sites
  • Centre Hospitalier d'Auxerre - Neonatology and pediatric emergency department
    Auxerre, Auxerre 89011, France
  • Dr Christine REGIMBART - Private Practice
    Bécon-les-Granits, Becon-les-Granits 49026, France
  • Scm Les Pediatrices Du Pic St Loup
    Saint-Clément, DE Riviere 34980, France
  • Dr. Anne Sengier - Private Practice
    Le Havre, LE Havre 76600, France
  • Centre Hospitalier de Montauban - Pediatric Department
    Montauban, Montauban, France
  • Centre Hospitalier Universitaire de Nantes - Pediatric emergency department
    Nantes, Nantes 44093, France
  • Hôpital NOVO - Pediatric department
    Pontoise, Pontoise 95300, France
  • Dr Marta Nowak-Mohamed - Private Practice
    Vichy, Vichy 03200, France
  • Dr Frederic Couttenier Private Practice
    Attiches, 59551, France
  • Elise Foy-Foulkes Private Practice
    Boulogne-Billancourt, 92100, France
  • Dr. Anne Cheve Private Practice
    Brest, 29200, France
  • Dr. Sandra Brancato Private Practice
    Brignon, 30190, France
  • Dr. Karim Abada Private Practice
    Foix, 09017, France
  • Dr. Nellie Houeto Private Practice
    Hyères, 83400, France
  • Dr. Amandine Blasquez Private Practice
    Libourne, 33500, France
  • Dr. Marc Sznajder Private Practice
    Paris, 75011, France
  • Dr. Piotr Gembara Private Practice
    Vichy, 03200, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Oct 2025, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 19, 2024
StartActual
Mar 12, 2024
Primary completionActual
Oct 31, 2025
CompletionActual
Dec 31, 2025
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318117
Collaborators
BioFortis
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Mar 12, 2024
Primary completion
Oct 31, 2025
Completion
Dec 31, 2025
Last update
Jan 30, 2026

Study contacts

Hugues Piloquet, MD
principal investigator · CHU Nantes Children's chronic disease service

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion